Skip to content
Clinical Trials – home

Ospedale Fabrizio Spaziani

Research site

Italy Via Armando Fabi Snc, 03100 Frosinone, Italy

  • 2 trials recruiting
  • Acute myeloid leukaemia · Breast cancer · Cardiovascular disorder
  • Adult patients

About Specializations

Ospedale Fabrizio Spaziani in Frosinone, Italy specialises in clinical trials of conditions such as Acute myeloid leukaemia, Breast cancer, Cardiovascular disorder, Colorectal cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Research

The site focuses on cardiovascular disease trials aiming to improve outcomes for patients with high risk or established disease. Studies evaluate innovative peptide therapies to lower event rates in individuals with hypertension and existing heart conditions.

  • Risk reduction in hypertension
  • Evaluation of novel peptide therapeutics
  • Assessment of cardiovascular event endpoints

At Ospedale Fabrizio Spaziani, investigators are exploring strategies to lower cardiovascular events in patients with hypertension and established heart disease.

Hematologic Oncology

Research at the department includes Acute Lymphoblastic Leukemia studies that test chemo‑free regimens to enhance survival. Trials in Acute Myeloid Leukemia evaluate targeted antibody‑drug conjugates to achieve deeper remission.

  • Chemo‑free induction strategies
  • Monoclonal antibody consolidation
  • Minimal residual disease eradication

The oncology clinic is enrolling adult patients to assess innovative therapies that may reduce treatment toxicity while maintaining efficacy.

Solid Tumor Studies

The center conducts breast cancer trials comparing sequential versus concurrent endocrine and chemotherapy to prevent recurrence. In metastatic colorectal cancer research, investigators examine optimal sequencing of targeted agents to extend overall survival.

  • Sequencing of anti‑EGFR and multikinase inhibitors
  • Hormone‑therapy timing in early breast cancer
  • Combination strategies in colorectal cancer

These studies at the Ambulatorio di Oncologia aim to refine treatment pathways for common cancers affecting the region.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Armando Fabi Snc03100 FrosinoneItaly
Recruiting now
2 trials
Conditions studied
7

More sites in FrosinoneItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

6 clinical trials

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:IRCCS Ospedale Policlinico San Martino

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Fondazione GONO G.I.

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.